With a market capitalization (market cap) of $1.87B — a measure of how much the company is worth — Kardigan, Inc. is the 2157th most valuable company in Healthcare as of August 18, 2026. Shares trade at $20.92, up +1.80% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Visit websiteAs of August 18, 2026, Kardigan, Inc. (KARD) is worth $1.87B — this is its market capitalization, the total value of all its outstanding shares.
Kardigan, Inc.’s market cap is $1.87B, which ranks it #2157 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Kardigan, Inc. (KARD) shares trade at $20.92, up 1.80% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025